Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Advances on research and development contract services, from Theradex	$ 185,392	$ 202,816
Research and development contract liabilities, Theradex	$ 88,162	$ 18,436
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	47,875,814	45,483,097
Common stock, shares outstanding	47,875,814	45,483,097
Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.0001
Preferred stock, stated value	10.00
Preferred stock, per share redemption price	$ 50.00
Preferred stock, shares authorized	175,000
Preferred stock, shares issued	175,000
Preferred stock, shares outstanding	175,000
Preferred stock, aggregate redemption value	$ 8,750,000
Preferred stock, issuable upon conversion	2,187,500